Literature DB >> 27742194

Fibroblast growth factor 23: fueling the fire.

Mark Hanudel1, Harald Jüppner2, Isidro B Salusky3.   

Abstract

In chronic kidney disease, systemic inflammation is common and associated with mortality. The present study demonstrates that fibroblast growth factor 23 (FGF23) contributes to uremic inflammation by increasing hepatic expression and secretion of inflammatory cytokines. FGF23 binds to hepatic FGFR4, inducing calcineurin/nuclear factor of activated T-cell signaling, resulting in increased expression of interleukin 6 and C-reactive protein. The proinflammatory effects of FGF23 are inhibited by an isoform-specific FGFR4 blocking antibody and by cyclosporine, a calcineurin inhibitor.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27742194      PMCID： PMC5914485          DOI： 10.1016/j.kint.2016.08.013

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


  9 in total

1.  FGF23 induces left ventricular hypertrophy.

Authors:  Christian Faul; Ansel P Amaral; Behzad Oskouei; Ming-Chang Hu; Alexis Sloan; Tamara Isakova; Orlando M Gutiérrez; Robier Aguillon-Prada; Joy Lincoln; Joshua M Hare; Peter Mundel; Azorides Morales; Julia Scialla; Michael Fischer; Elsayed Z Soliman; Jing Chen; Alan S Go; Sylvia E Rosas; Lisa Nessel; Raymond R Townsend; Harold I Feldman; Martin St John Sutton; Akinlolu Ojo; Crystal Gadegbeku; Giovana Seno Di Marco; Stefan Reuter; Dominik Kentrup; Klaus Tiemann; Marcus Brand; Joseph A Hill; Orson W Moe; Makoto Kuro-O; John W Kusek; Martin G Keane; Myles Wolf
Journal:  J Clin Invest       Date:  2011-10-10       Impact factor: 14.808

2.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

Authors:  Tamara Isakova; Huiliang Xie; Wei Yang; Dawei Xie; Amanda Hyre Anderson; Julia Scialla; Patricia Wahl; Orlando M Gutiérrez; Susan Steigerwalt; Jiang He; Stanley Schwartz; Joan Lo; Akinlolu Ojo; James Sondheimer; Chi-yuan Hsu; James Lash; Mary Leonard; John W Kusek; Harold I Feldman; Myles Wolf
Journal:  JAMA       Date:  2011-06-15       Impact factor: 56.272

3.  Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.

Authors:  Alexander Grabner; Ansel P Amaral; Karla Schramm; Saurav Singh; Alexis Sloan; Christopher Yanucil; Jihe Li; Lina A Shehadeh; Joshua M Hare; Valentin David; Aline Martin; Alessia Fornoni; Giovana Seno Di Marco; Dominik Kentrup; Stefan Reuter; Anna B Mayer; Hermann Pavenstädt; Jörg Stypmann; Christian Kuhn; Susanne Hille; Norbert Frey; Maren Leifheit-Nestler; Beatrice Richter; Dieter Haffner; Reimar Abraham; Johannes Bange; Bianca Sperl; Axel Ullrich; Marcus Brand; Myles Wolf; Christian Faul
Journal:  Cell Metab       Date:  2015-10-01       Impact factor: 27.287

4.  FGF23 signaling impairs neutrophil recruitment and host defense during CKD.

Authors:  Jan Rossaint; Jessica Oehmichen; Hugo Van Aken; Stefan Reuter; Hermann J Pavenstädt; Melanie Meersch; Mark Unruh; Alexander Zarbock
Journal:  J Clin Invest       Date:  2016-02-15       Impact factor: 14.808

Review 5.  Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.

Authors:  Tamara Isakova; Joachim H Ix; Stuart M Sprague; Kalani L Raphael; Linda Fried; Jennifer J Gassman; Dominic Raj; Alfred K Cheung; John W Kusek; Michael F Flessner; Myles Wolf; Geoffrey A Block
Journal:  J Am Soc Nephrol       Date:  2015-05-12       Impact factor: 10.121

6.  Fibroblast growth factor 23 and Inflammation in CKD.

Authors:  Jair Munoz Mendoza; Tamara Isakova; Ana C Ricardo; Huiliang Xie; Sankar D Navaneethan; Amanda H Anderson; Lydia A Bazzano; Dawei Xie; Matthias Kretzler; Lisa Nessel; L Lee Hamm; Lavinia Negrea; Mary B Leonard; Dominic Raj; Myles Wolf
Journal:  Clin J Am Soc Nephrol       Date:  2012-05-03       Impact factor: 8.237

7.  Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease.

Authors:  Daniela V Barreto; Fellype C Barreto; Sophie Liabeuf; Mohammed Temmar; Horst-Dieter Lemke; Christophe Tribouilloy; Gabriel Choukroun; Raymond Vanholder; Ziad A Massy
Journal:  Kidney Int       Date:  2009-12-16       Impact factor: 10.612

8.  Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease.

Authors:  Saurav Singh; Alexander Grabner; Christopher Yanucil; Karla Schramm; Brian Czaya; Stefanie Krick; Mark J Czaja; Rene Bartz; Reimar Abraham; Giovana S Di Marco; Marcus Brand; Myles Wolf; Christian Faul
Journal:  Kidney Int       Date:  2016-07-22       Impact factor: 10.612

9.  Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production.

Authors:  Valentin David; Aline Martin; Tamara Isakova; Christina Spaulding; Lixin Qi; Veronica Ramirez; Kimberly B Zumbrennen-Bullough; Chia Chi Sun; Herbert Y Lin; Jodie L Babitt; Myles Wolf
Journal:  Kidney Int       Date:  2016-01-04       Impact factor: 10.612
  9 in total
  3 in total

1.  Association between mineral and bone disorder in patients with acute kidney injury following cardiac surgery and adverse outcomes.

Authors:  Tianye Yang; Wenji Wang; Xiao Tang; Peng Shi; Lulu Zhang; Wenyan Yu; Yingxin Xie; Daqiao Guo; Feng Ding
Journal:  BMC Nephrol       Date:  2019-10-15       Impact factor: 2.388

Review 2.  The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia.

Authors:  Brian Czaya; Christian Faul
Journal:  Int J Mol Sci       Date:  2019-08-27       Impact factor: 5.923

3.  Low Klotho/Fibroblast Growth Factor 23 Ratio Is an Independent Risk Factor for Renal Progression in Chronic Kidney Disease: Finding From KNOW-CKD.

Authors:  Hyo Jin Kim; Yunmi Kim; Minjung Kang; Seonmi Kim; Sue Kyung Park; Suah Sung; Young Youl Hyun; Ji Yong Jung; Curie Ahn; Kook-Hwan Oh
Journal:  Front Med (Lausanne)       Date:  2022-07-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.